Anacor Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANAC)

$99.06 -0.14 (-0.14 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$99.20
Today's Range$99.06 - $99.06
52-Week Range$52.00 - $156.93
Volume300 shs
Average Volume1.81 million shs
Market Capitalization$4.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.53

About Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals logoAnacor Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis. Its product, KERYDIN (tavaborole) topical solution, approximately 5%, is an oxaborole antifungal approved by the United States Food and Drug Administration (FDA) for the topical treatment of onychomycosis of the toenails. It also has a pipeline of other internally discovered topical and systemic boron-based compounds in early-stages of research and development, which include AN3365. Its compound, AN5568 (SCYX-7158), is licensed to Drugs for Neglected Diseases initiative (DNDi) for the treatment of human African trypanosomiasis.

Receive ANAC News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:ANAC
CUSIP03242010
Phone+1-650-5437500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.45)
Net IncomeN/A
Net Margins-92.08%
Return on Equity-133.71%
Return on Assets-38.09%

Miscellaneous

EmployeesN/A
Outstanding Shares44,860,000

Anacor Pharmaceuticals (NASDAQ:ANAC) Frequently Asked Questions

What is Anacor Pharmaceuticals' stock symbol?

Anacor Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANAC."

How were Anacor Pharmaceuticals' earnings last quarter?

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) released its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.01. The biopharmaceutical company earned $17.54 million during the quarter, compared to analyst estimates of $19.53 million. Anacor Pharmaceuticals had a negative net margin of 92.08% and a negative return on equity of 133.71%. Anacor Pharmaceuticals's revenue for the quarter was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. View Anacor Pharmaceuticals' Earnings History.

Who are some of Anacor Pharmaceuticals' key competitors?

How do I buy Anacor Pharmaceuticals stock?

Shares of Anacor Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anacor Pharmaceuticals' stock price today?

One share of Anacor Pharmaceuticals stock can currently be purchased for approximately $99.06.

How big of a company is Anacor Pharmaceuticals?

Anacor Pharmaceuticals has a market capitalization of $4.50 billion.

How can I contact Anacor Pharmaceuticals?

Anacor Pharmaceuticals' mailing address is 1020 E Meadow Cir, PALO ALTO, CA 94303-4230, United States. The biopharmaceutical company can be reached via phone at +1-650-5437500.


MarketBeat Community Rating for Anacor Pharmaceuticals (ANAC)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about Anacor Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anacor Pharmaceuticals (NASDAQ:ANAC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AHoldBuyBuy
Consensus Rating Score: N/A2.332.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$99.25$101.17$101.17
Price Target Upside: N/A0.74% downside1.18% upside1.18% upside

Anacor Pharmaceuticals (NASDAQ:ANAC) Consensus Price Target History

Price Target History for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ:ANAC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2016MizuhoDowngradeBuy -> Neutral$98.00 -> $99.25N/AView Rating Details
5/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
5/16/2016WedbushDowngradeOutperform -> Neutral$148.00 -> $99.25N/AView Rating Details
5/10/2016CowenReiterated RatingBuyN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Anacor Pharmaceuticals (NASDAQ:ANAC) Earnings History and Estimates Chart

Earnings by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ ANAC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.35)($0.36)$19.53 million$17.54 millionViewListenView Earnings Details
2/29/2016Q415($0.30)($0.43)$27.93 million$21.20 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.37)$25.60 million$24.60 millionViewListenView Earnings Details
8/6/2015Q215($0.32)($0.30)$18.55 million$21.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.47)($0.30)$9.20 million$15.26 millionViewN/AView Earnings Details
3/12/2015Q414($0.59)($0.21)$4.74 million$9.60 millionViewN/AView Earnings Details
11/6/2014Q314($0.65)($0.74)$3.67 million$3.96 millionViewN/AView Earnings Details
8/7/2014Q214($0.63)($0.58)$3.03 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.39)($0.51)$2.82 million$4.15 millionViewN/AView Earnings Details
3/13/2014Q413$3.01$3.01$2.85 million$8.50 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.39)($0.36)$2.60 million$3.40 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.39)($0.42)$2.57 million$1.71 billionViewN/AView Earnings Details
3/14/2013Q4 2012($0.45)($0.36)$3.25 million$3.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.45)($0.46)$3.18 million$2.47 millionViewN/AView Earnings Details
8/9/2012($0.45)($0.47)ViewN/AView Earnings Details
5/10/2012($0.44)($0.48)ViewN/AView Earnings Details
3/13/2012($0.35)($0.52)ViewN/AView Earnings Details
11/10/2011($0.41)($0.16)ViewN/AView Earnings Details
8/11/2011($0.45)($0.54)ViewN/AView Earnings Details
5/5/2011($0.31)($0.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Anacor Pharmaceuticals (NASDAQ:ANAC) Earnings Estimates

2017 EPS Consensus Estimate: $2.98
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.53)($0.53)($0.53)
Q2 20171$0.52$0.52$0.52
Q3 20171$1.32$1.32$1.32
Q4 20171$1.67$1.67$1.67
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Anacor Pharmaceuticals (NASDAQ:ANAC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Anacor Pharmaceuticals (NASDAQ ANAC) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)
Insider Trades by Quarter for Anacor Pharmaceuticals (NASDAQ:ANAC)

Anacor Pharmaceuticals (NASDAQ ANAC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2016Graeme BellCFOSell751$99.28$74,559.28View SEC Filing  
5/23/2016Keith R LeonardDirectorSell9,000$99.70$897,300.00View SEC Filing  
5/16/2016Anders D HoveDirectorSell353,881$99.59$35,243,008.79View SEC Filing  
4/29/2016Ryan T SullivanEVPSell3,125$66.33$207,281.25View SEC Filing  
4/8/2016Anders D HoveDirectorSell229,301$71.10$16,303,301.10View SEC Filing  
3/22/2016Paul L BernsCEOSell37,500$60.31$2,261,625.00View SEC Filing  
1/19/2016Vincent P. IppolitoEVPSell20,000$95.41$1,908,200.00View SEC Filing  
1/15/2016Lee ZaneSVPSell1,466$89.57$131,309.62View SEC Filing  
1/4/2016Paul L. BernsCEOSell2,533$112.35$284,582.55View SEC Filing  
1/4/2016Ryan T. SullivanVPSell733$111.78$81,934.74View SEC Filing  
1/4/2016Vincent P. IppolitoEVPSell855$112.28$95,999.40View SEC Filing  
12/11/2015Paul L. BernsCEOSell20,000$117.26$2,345,200.00View SEC Filing  
12/10/2015Ryan T. SullivanVPSell10,000$110.41$1,104,100.00View SEC Filing  
9/15/2015Lee ZaneSVPSell14,000$139.84$1,957,760.00View SEC Filing  
9/15/2015Paul L. BernsCEOSell20,000$139.83$2,796,600.00View SEC Filing  
8/13/2015Paul L BernsCEOSell20,000$138.69$2,773,800.00View SEC Filing  
6/15/2015Lee ZaneSVPSell12,000$69.05$828,600.00View SEC Filing  
5/15/2015Jacob J PlattnerVPSell8,920$63.73$568,471.60View SEC Filing  
5/14/2015Carmen R RodriguezVPSell61,942$62.73$3,885,621.66View SEC Filing  
4/29/2015Ryan T SullivanVPSell3,125$53.61$167,531.25View SEC Filing  
4/27/2015Paul L BernsCEOSell50,000$63.64$3,182,000.00View SEC Filing  
4/15/2015Jacob J PlattnerVPSell8,920$62.81$560,265.20View SEC Filing  
3/23/2015Geoffrey M ParkerCFOBuy3,000$52.43$157,290.00View SEC Filing  
3/16/2015Jacob J PlattnerVPSell8,920$55.60$495,952.00View SEC Filing  
3/16/2015Lee ZaneSVPSell12,000$56.44$677,280.00View SEC Filing  
3/4/2015Sanjay ChandaSVPSell5,000$45.00$225,000.00View SEC Filing  
3/3/2015Vincent P IppolitoEVPSell9,000$43.88$394,920.00View SEC Filing  
3/2/2015Jacob J PlattnerVPSell6,875$44.02$302,637.50View SEC Filing  
3/2/2015Kirk R MaplesSVPSell600$43.95$26,370.00View SEC Filing  
1/2/2015Jacob J PlattnerVPSell6,875$32.09$220,618.75View SEC Filing  
12/26/2014Paul L BernsCEOSell25,000$30.82$770,500.00View SEC Filing  
12/12/2014Lucy ShapiroDirectorSell289,685$35.11$10,170,840.35View SEC Filing  
12/11/2014Lee ZaneSVPSell4,900$36.09$176,841.00View SEC Filing  
12/9/2014Kirk R MaplesSVPSell60,000$36.52$2,191,200.00View SEC Filing  
12/1/2014Jacob J PlattnerVPSell6,875$33.34$229,212.50View SEC Filing  
12/1/2014Kirk R MaplesSVPSell600$33.38$20,028.00View SEC Filing  
11/26/2014Sanjay ChandaSVPSell5,000$35.00$175,000.00View SEC Filing  
11/3/2014Jacob J PlattnerVPSell6,875$29.32$201,575.00View SEC Filing  
10/1/2014Jacob J PlattnerVPSell6,875$24.47$168,231.25View SEC Filing  
9/26/2014Anders D HoveDirectorSell20,000$25.00$500,000.00View SEC Filing  
9/19/2014Anders D HoveDirectorSell740,000$24.87$18,403,800.00View SEC Filing  
9/16/2014Anders D HoveDirectorSell90,000$24.99$2,249,100.00View SEC Filing  
9/10/2014Sanjay ChandaSVPSell10,000$24.25$242,500.00View SEC Filing  
9/8/2014Geoffrey M ParkerCFOBuy6,590$21.82$143,793.80View SEC Filing  
8/27/2014Mark LeschlyDirectorSell13,067$22.50$294,007.50View SEC Filing  
5/20/2014Kirk MaplesSVPSell1,500$14.15$21,225.00View SEC Filing  
4/21/2014Kirk MaplesSVPSell1,500$15.60$23,400.00View SEC Filing  
3/24/2014Geoffrey ParkerCFOBuy5,000$20.11$100,550.00View SEC Filing  
3/21/2014Lucy ShapiroDirectorSell80,000$21.14$1,691,200.00View SEC Filing  
3/20/2014Kirk MaplesSVPSell3,000$22.39$67,170.00View SEC Filing  
3/18/2014Geoffrey ParkerCFOBuy2,410$22.60$54,466.00View SEC Filing  
3/5/2014David PerryCEOSell65,000$20.22$1,314,300.00View SEC Filing  
2/20/2014Kirk MaplesSVPSell3,000$19.33$57,990.00View SEC Filing  
2/5/2014David PerryCEOSell15,000$17.00$255,000.00View SEC Filing  
1/21/2014Kirk MaplesSVPSell3,000$20.27$60,810.00View SEC Filing  
1/9/2014David PerryCEOSell65,000$16.32$1,060,800.00View SEC Filing  
12/9/2013David PerryCEOSell40,328$16.23$654,523.44View SEC Filing  
11/26/2013Geoffrey ParkerCFOBuy10,000$13.40$134,000.00View SEC Filing  
11/25/2013Geoffrey ParkerCFOBuy10,000$12.85$128,500.00View SEC Filing  
8/14/2013Kirk MaplesSVPSell1,052$9.71$10,214.92View SEC Filing  
8/13/2013Geoffrey ParkerCFOBuy50,000$8.34$417,000.00View SEC Filing  
6/19/2013Geoffrey M ParkerCFOBuy23,046$5.20$119,839.20View SEC Filing  
6/18/2013Geoffrey M ParkerCFOBuy20,000$5.22$104,400.00View SEC Filing  
6/14/2013Kirk R MaplesSVPSell5,600$5.39$30,184.00View SEC Filing  
11/26/2012Kirk R MaplesSVPSell3,000$5.22$15,660.00View SEC Filing  
11/1/2012Kirk R MaplesSVPSell3,000$5.81$17,430.00View SEC Filing  
10/5/2012Lucy ShapiroDirectorSell30,000$6.67$200,100.00View SEC Filing  
8/22/2012Geoffrey M ParkerCFOBuy5,000$6.19$30,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anacor Pharmaceuticals (NASDAQ ANAC) News Headlines

Source:
DateHeadline
Repros Therapeutics (RPRX) & Anacor Pharmaceuticals (ANAC) Head-To-Head AnalysisRepros Therapeutics (RPRX) & Anacor Pharmaceuticals (ANAC) Head-To-Head Analysis
www.americanbankingnews.com - December 6 at 8:02 AM
Reviewing Genomic Health (GHDX) & Anacor Pharmaceuticals (ANAC)Reviewing Genomic Health (GHDX) & Anacor Pharmaceuticals (ANAC)
www.americanbankingnews.com - November 28 at 9:08 PM
Anacor Pharmaceuticals (ANAC) and Its Rivals Critical ComparisonAnacor Pharmaceuticals (ANAC) and Its Rivals Critical Comparison
www.americanbankingnews.com - November 25 at 3:20 PM
Comparing Anacor Pharmaceuticals (ANAC) and The CompetitionComparing Anacor Pharmaceuticals (ANAC) and The Competition
www.americanbankingnews.com - November 22 at 8:05 AM
Upcoming Earnings: Pfizer Reports Tomorrow As Management Explores Alternatives For Consumer HealthcareUpcoming Earnings: Pfizer Reports Tomorrow As Management Explores Alternatives For Consumer Healthcare
finance.yahoo.com - October 30 at 4:49 PM
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley FoolBetter Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool
www.fool.com - September 17 at 3:41 PM
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley FoolBetter Buy: Pfizer Inc. vs. Bristol-Myers Squibb -- The Motley Fool - Motley Fool
www.fool.com - September 17 at 3:40 PM
Suneva Medical Expands their Prestigious Board of Directors with the Appointment of Vince IppolitoSuneva Medical Expands their Prestigious Board of Directors with the Appointment of Vince Ippolito
www.prnewswire.com - August 28 at 3:58 PM
Heres How Much $10,000 Invested in Pfizer in 1977 Is Worth Now ... - Motley FoolHere's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now ... - Motley Fool
www.fool.com - August 21 at 9:00 PM
Shire chief financial officer joins Boston ag-tech startupShire chief financial officer joins Boston ag-tech startup
www.bizjournals.com - August 21 at 4:00 PM
Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff - TheStreet.comPfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff - TheStreet.com
www.thestreet.com - July 31 at 3:57 PM
Pharma Giant Pfizer Reports Q2 Earnings Tomorrow Morning - Seeking AlphaPharma Giant Pfizer Reports Q2 Earnings Tomorrow Morning - Seeking Alpha
seekingalpha.com - July 31 at 3:57 PM
These 2 Pharma Giants May Be on Pfizers M&A Radar Right Now ... - Motley FoolThese 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now ... - Motley Fool
www.fool.com - July 26 at 4:23 PM
The Stock Market Is Very Expensive: 5 Safe Blue Chips to Buy NowThe Stock Market Is Very Expensive: 5 Safe Blue Chips to Buy Now
247wallst.com - July 24 at 1:15 PM
3 Dividend Stocks That Are Minting Money -- The Motley Fool - Motley Fool3 Dividend Stocks That Are Minting Money -- The Motley Fool - Motley Fool
www.fool.com - July 13 at 9:46 PM
North America Will Continue to be the Most Lucrative Market for ... - PR Newswire (press release)North America Will Continue to be the Most Lucrative Market for ... - PR Newswire (press release)
www.prnewswire.com - June 27 at 3:37 PM
3 Stocks to Help You Build Retirement Wealth -- The Motley Fool - Motley Fool3 Stocks to Help You Build Retirement Wealth -- The Motley Fool - Motley Fool
www.fool.com - June 25 at 8:43 PM
Top 3 Emerging Trends Impacting the Global Anti-Inflammatory ... - Business Wire (press release)Top 3 Emerging Trends Impacting the Global Anti-Inflammatory ... - Business Wire (press release)
www.businesswire.com - June 23 at 9:05 PM
Spherix Inc. Announces Definitive Terms Reached to Acquire ... - PR Newswire (press release)Spherix Inc. Announces Definitive Terms Reached to Acquire ... - PR Newswire (press release)
www.prnewswire.com - June 20 at 4:09 PM
Pfizer unloading space after $14 billion Medivation dealPfizer unloading space after $14 billion Medivation deal
www.bizjournals.com - May 8 at 11:01 AM
PFIZER REPORTS FIRST-QUARTER 2017 RESULTSPFIZER REPORTS FIRST-QUARTER 2017 RESULTS
www.businesswire.com - May 2 at 7:52 AM
Biotech M&A Plunges as Trump Attacks Drug Companies - InvestopediaBiotech M&A Plunges as Trump Attacks Drug Companies - Investopedia
www.investopedia.com - April 24 at 3:34 PM
Canadas Cannabis Boom Creating a $30 Billion Investment Opportunity - Baystreet.caCanada's Cannabis Boom Creating a $30 Billion Investment Opportunity - Baystreet.ca
www.baystreet.ca - April 20 at 3:36 PM
5 Stocks to Watch as Canada Gets Hooked on Cannabis - PR Newswire (press release)5 Stocks to Watch as Canada Gets Hooked on Cannabis - PR Newswire (press release)
www.prnewswire.com - April 18 at 8:34 AM
1 Top Stock in Big Pharma -- The Motley Fool - Motley Fool1 Top Stock in Big Pharma -- The Motley Fool - Motley Fool
www.fool.com - March 27 at 7:32 AM
1 Top Stock in Big Pharma - Motley Fool1 Top Stock in Big Pharma - Motley Fool
www.fool.com - March 25 at 11:40 AM
Buy Pfizer: Income Play With Good Growth ComingBuy Pfizer: Income Play With Good Growth Coming
seekingalpha.com - March 17 at 3:38 PM
These Were the 10 Biggest Pharmaceutical Deals of 2016 - FortuneThese Were the 10 Biggest Pharmaceutical Deals of 2016 - Fortune
fortune.com - February 24 at 3:44 PM
Better Buy: Pfizer Inc. vs. Merck & Co. Inc. -- The Motley Fool - Motley FoolBetter Buy: Pfizer Inc. vs. Merck & Co. Inc. -- The Motley Fool - Motley Fool
www.fool.com - February 21 at 3:48 PM
4 High-Yield Dividend Stocks You Dont Have to Babysit - Motley Fool4 High-Yield Dividend Stocks You Don't Have to Babysit - Motley Fool
www.fool.com - February 16 at 8:27 AM
5 Things Pfizers Management Wants You to Know - Motley Fool5 Things Pfizer's Management Wants You to Know - Motley Fool
www.fool.com - February 1 at 3:37 PM
Top 5 Vendors in the Global Atopic Dermatitis Drugs Market from 2017 to 2021: Technavio - Business Wire (press release)Top 5 Vendors in the Global Atopic Dermatitis Drugs Market from 2017 to 2021: Technavio - Business Wire (press release)
www.businesswire.com - February 1 at 3:37 PM
Are Pfizers Acquisitions Holding Back Its Bottom Line? - 24/7 Wall St.Are Pfizer's Acquisitions Holding Back Its Bottom Line? - 24/7 Wall St.
247wallst.com - January 31 at 3:42 PM
3 Reasons to Buy Pfizer Stock and Never Sell -- The Motley Fool - Motley Fool3 Reasons to Buy Pfizer Stock and Never Sell -- The Motley Fool - Motley Fool
www.fool.com - January 31 at 2:25 AM
All Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter ... - TheStreet.comAll Eyes on Growth Plans as Pfizer Gears Up for Fourth Quarter ... - TheStreet.com
www.thestreet.com - January 31 at 2:25 AM
A Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour - BenzingaA Mixed Bag of Earnings Ahead: Eli Lilly, Pfizer, Exxon Mobil, And Under Armour - Benzinga
www.benzinga.com - January 30 at 3:54 PM
Drugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees - TheStreet.comDrugmakers Plan Huge Deals in 2017 -- and Banks Will Collect Big Fees - TheStreet.com
www.thestreet.com - January 24 at 8:28 PM

SEC Filings

Anacor Pharmaceuticals (NASDAQ:ANAC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anacor Pharmaceuticals (NASDAQ:ANAC) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anacor Pharmaceuticals (NASDAQ ANAC) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.